Intensive Care Unit requirements in patients treated with immune checkpoint inhibitors
Affiliation
Departments of Acute Medicine, Medical Oncology and Critical Care, The Christie, Wilmslow Road, Manchester, UK.Issue Date
2022
Metadata
Show full item recordAbstract
Objective: To determine the proportion of emergency patients treated with immune checkpoint inhibitors (ICIs) that require critical care admission and their requirements. Design: Prospective case series. Methods: Analysis of acutely unwell patients treated with ICIs attending a tertiary UK cancer hospital between May 2018 and May 2022. The primary outcome measure was the percentage of patients treated with ICI therapy requiring ICU admission. The secondary outcome measure was whether this need was driven by an immune-mediated toxicity. Results: Eighteen (1.2%) patients of the 1561 acutely admitted patients treated with ICI therapy required an admission to ICU. Ten (55.5%) patients were admitted due to an immune-mediated toxicity; 4 due to pneumonitis and 4 due to myasthenia gravis. Seven of 10 survived their ICU admission with 6 surviving at least 6 month post ICU discharge. Conclusions: Only a small minority of emergency admissions in patients treated with ICIs require admission to ICU. This series adds further evidence that patients with organ failure due to immune-mediated toxicity may achieve good outcomes from ICU admission.Citation
Cooksley T, Weaver JMJ, Haji-Michael P. Intensive Care Unit requirements in patients treated with immune checkpoint inhibitors. QJM : monthly journal of the Association of Physicians. 2022 Nov 15. PubMed PMID: 36377790. Epub 2022/11/16. eng.Journal
QJMDOI
10.1093/qjmed/hcac258PubMed ID
36377790Additional Links
https://dx.doi.org/10.1093/qjmed/hcac258Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/qjmed/hcac258
Scopus Count
Collections
Related articles
- Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors.
- Authors: Lin L, Houwink API, van Dieren JM, Wolthuis EK, van Thienen JV, van der Heijden MS, Haanen JBAG, Beijnen JH, Huitema ADR
- Issue date: 2024 Jun
- Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series.
- Authors: Rajendram P, Torbic H, Duggal A, Campbell J, Hovden M, Dhawan V, Pastores SM, Gutierrez C
- Issue date: 2021 Oct
- ICU admission for solid cancer patients treated with immune checkpoint inhibitors.
- Authors: Toffart AC, Meert AP, Wallet F, Gibelin A, Guisset O, Gonzalez F, Seguin A, Kouatchet A, Delaunay M, Debieuvre D, Duchemann B, Rousseau-Bussac G, Nyunga M, Grimaldi D, Levrat A, Azoulay E, Lemiale V
- Issue date: 2023 Apr 18
- Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE).
- Authors: Ahern E, Allen MJ, Schmidt A, Lwin Z, Hughes BGM
- Issue date: 2021 Apr
- Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
- Authors: Lipe DN, Galvis-Carvajal E, Rajha E, Wechsler AH, Gaeta S
- Issue date: 2021 Aug